Evidence map›Paper›PMID 38711445›Full record

ArticleiScience2024

The different impact of drug-resistant

Míriam Díaz-Varela, Andrea Sanchez-Hidalgo, Sandra Calderon-Copete, Virginie Tacchini, Tobias R Shipley, Lady Giovanna Ramírez, Julien Marquis, Olga Lucía Fernández, Nancy Gore Saravia, Fabienne Tacchini-Cottier

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Míriam Díaz-VarelaDepartment of Immunobiology, WHO Collaborative Center for Research and Training in Immunology, University of Lausanne, 1066 Epalinges, Switzerland.
Andrea Sanchez-HidalgoCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali 760031, Colombia.
Sandra Calderon-CopeteLausanne Genomic Technologies Facility, University of Lausanne, 1015 Lausanne, Switzerland.
Virginie TacchiniDepartment of Immunobiology, WHO Collaborative Center for Research and Training in Immunology, University of Lausanne, 1066 Epalinges, Switzerland.
Tobias R ShipleyDepartment of Immunobiology, WHO Collaborative Center for Research and Training in Immunology, University of Lausanne, 1066 Epalinges, Switzerland.
Lady Giovanna RamírezCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali 760031, Colombia.
Julien MarquisLausanne Genomic Technologies Facility, University of Lausanne, 1015 Lausanne, Switzerland.
Olga Lucía FernándezCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali 760031, Colombia.
Nancy Gore SaraviaCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali 760031, Colombia.
Fabienne Tacchini-CottierDepartment of Immunobiology, WHO Collaborative Center for Research and Training in Immunology, University of Lausanne, 1066 Epalinges, Switzerland.

Funding

The Innate Immune Response As A Therapeutic Target For Cutaneous LeishmaniasisU19AI129910 · NIAID · CENTRO INTERNACIONAL (CIDEIM) · PI GOMEZ, MARIA ADELAIDA · 2017 to 2021
$2.8M
NIAID NIH HHS U19 AI129910Wellcome Trust
6 · The paper itself

Abstract

Drug resistance threatens the effective control of infections, including parasitic diseases such as leishmaniases. Neutrophils are essential players in antimicrobial control, but their role in drug-resistant infections is poorly understood. Here, we evaluated human neutrophil response to clinical parasite strains having distinct natural drug susceptibility. We found that

Indexed as

ImmunologyParasitology

Identifiers

PMID38711445
PMCPMC11070714

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.